Showing 2031-2040 of 2526 results for "".
- Johnson & Johnson Begins Testing COVID-19 Vaccine in Adolescentshttps://modernod.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/Johnson & Johnson announced that it has begun vaccinating adolescent participants in an ongoing phase 2a trial of its COVID-19 vaccine candidate Ad26.COV2.S. The study, which got under way last September, was initially designed to evaluate single- and two-dose regimens of the vaccine in healt
- Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenavahttps://modernod.com/news/outlook-therapeutics-reports-positive-safety-profile-from-norse-three-study-for-lytenava/2479037/Outlook Therapeutics announced positive topline results from its NORSE THREE open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases. Topline results from the open-label safety study demonstrated that ONS-5010 showed no unexpecte
- Zeiss Opens New High-Tech Center in San Francisco Bay Areahttps://modernod.com/news/zeiss-opens-new-high-tech-center-in-san-francisco-bay-area/2479038/Zeiss has completed construction of its new R&D, production, sales and customer service site in the San Francisco Bay Area. Bringing together hundreds of Zeiss employees and key functions under one roof, represents a major milestone in the company’s international innovation and growth
- Visus Therapeutics Initiates Phase 2 Clinical Trial of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-initiates-phase-2-clinical-trial-of-brimochol-for-the-treatment-of-presbyopia/2479013/Visus Therapeutics announced the commencement of its phase 2 clinical trial of Brimochol topical ophthalmic solution under investigation for the treatment of presbyopia. Brimochol is a proprietary pupil-modulating eye drop that combines two well-studied, FDA-approved pharmaceuticals: carb
- Eyenovia and Eversana Announce Partnership to Support the Potential Launch and Commercialization of MydCombi for Mydriasishttps://modernod.com/news/eyenovia-and-eversana-announce-partnership-to-support-the-potential-launch-and-commercialization-of-mydcombi-for-mydriasis/2479001/Eyenovia and Eversana announced a partnership to help commercialize MydCombi in the United States, if approved. This announcement follows the FDA’s recent acceptance of Eyenovia’s new drug application (NDA) for MydCombi, a fixed combination mydriatic (pupil dilation) agent. If approved, My
- MAGIC Trial to Assess Factors that Impact Clinical Outcomes of Ab-Interno Canaloplastyhttps://modernod.com/news/magic-trial-to-assess-factors-that-impact-clinical-outcomes-of-ab-interno-canaloplasty/2478993/To assess the various factors that impact the safety and efficacy outcomes of ab-interno canaloplasty, the multicenter “MAGIC” trial has been initiated at eight surgery centers in the United States. A tissue-sparing, implant-free MIGS procedure, ab-interno canaloplasty is akin to cardiac a
- Newly Formed Ophthalmology Foundation Will Improve Global Eye Care Through Educationhttps://modernod.com/news/newly-formed-ophthalmology-foundation-will-improve-global-eye-care-through-education/2478972/The newly incorporated nonprofit Ophthalmology Foundation is laying the groundwork to improve global eye care and ophthalmic practice, particularly in low-resource and underserved countries, according to a company news release. Led by a global board of ophthalmologists, ophthalmology professors,
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Johnson & Johnson Vision Introduces Acuvue Oasys Multifocal with Pupil Optimized Designhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-oasys-multifocal-with-pupil-optimized-design/2478970/Johnson & Johnson Vision has introduced a new eye care option for patients with presbyopia: Acuvue Oasys Multifocal Contact Lenses with Pupil Optimized Design. The new lens is now available in the United States and Canada.
- Allergan Launches Glaucoma in Perspective Apphttps://modernod.com/news/allergan-launches-glaucoma-in-perspective-app/2478950/Allergan has announced the launch of Glaucoma in Perspective (GiP), an app designed to help patients understand the impact of glaucoma, improve quality of life, and reduce disease progression by promoting treatment adherence. The GiP app has been produced and funded by Allergan, with consu